Deniz is a Professor of Neuroscience at Lund University and Honorary Professor at the University of Sydney. He has over 2 decades of experience and track record in the fields of cell and gene therapy with special focus on development of technologies for treatment of neurodegenerative diseases. His developed recombinant AAV vectors towards therapeutic delivery and for disease modeling in rodents and non-human primates. He has pioneered PD animal model based on the use of AAV vectors to express alpha-synuclein in nigral dopamine neurons. Furthermore, he has directed studies aimed at understanding the pathophysiological basis of L-DOPA induced dyskinesias and how advanced treatments using cell and gene-based therapies could alleviate these troubling side effects of oral L-DOPA medication.
Lead PI (Core Leadership)
Deniz Kirik, MD, PhD
Lund University
Deniz is a Professor of Neuroscience at Lund University and Honorary Professor at the University of Sydney. He has over 2 decades of experience and track record in the fields of cell and gene therapy with special focus on development of technologies for treatment of neurodegenerative diseases. His developed recombinant AAV vectors towards therapeutic delivery and for disease modeling in rodents and non-human primates. He has pioneered PD animal model based on the use of AAV vectors to express alpha-synuclein in nigral dopamine neurons. Furthermore, he has directed studies aimed at understanding the pathophysiological basis of L-DOPA induced dyskinesias and how advanced treatments using cell and gene-based therapies could alleviate these troubling side effects of oral L-DOPA medication.
